Developing a Patient-Directed Policy Framework for Managing Orphan and Ultra-Orphan Drugs Throughout Their Lifecycle

被引：0
|
作者：
Devidas Menon
Tania Stafinski
Andrea Dunn
Durhane Wong-Rieger
机构：
[1] University of Alberta,Health Technology and Policy Unit, School of Public Health
[2] Canadian Organization for Rare Disorders,undefined
来源：
The Patient - Patient-Centered Outcomes Research | 2015年 / 8卷
关键词：
Rare Disease; Orphan Drug; Policy Framework; Patient Input; Decision Uncertainty;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：103 / 117
页数：14
相关论文
共 28 条
  • [11] Involving Patients in Reducing Decision Uncertainties Around Orphan and Ultra-Orphan Drugs: A Rare Opportunity?
    Devidas Menon
    Tania Stafinski
    Andrea Dunn
    Hilary Short
    [J]. The Patient - Patient-Centered Outcomes Research, 2015, 8 : 29 - 39
  • [12] REIMBURSEMENT OF ULTRA-ORPHAN MEDICINES: A NEW BEST-PRACTICE FRAMEWORK?
    Macaulay, R.
    Khatri, U.
    [J]. VALUE IN HEALTH, 2019, 22 : S861 - S861
  • [13] The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic review
    Schuller, Y.
    Hollak, C. E. M.
    Biegstraaten, M.
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2015, 10
  • [14] The quality of economic evaluations of ultra-orphan drugs in Europe – a systematic review
    Y. Schuller
    C. E. M. Hollak
    M. Biegstraaten
    [J]. Orphanet Journal of Rare Diseases, 10
  • [15] THE SMC ULTRA-ORPHAN FRAMEWORK: 3-YEAR REPORT CARD
    Macaulay, R.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S344 - S344
  • [16] FDA approves ultra-orphan drug on a 4-patient trial
    Mullard, Asher
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (10) : 669 - 669
  • [17] FDA approves ultra-orphan drug on a 4-patient trial
    Asher Mullard
    [J]. Nature Reviews Drug Discovery, 2015, 14 : 669 - 669
  • [18] ANALYSIS OF THE ULTRA-ORPHAN DRUGS APPROVED BY THE FDA IN THE PERIOD 1983-2014
    Thumar, R.
    Seoane-Vazquez, E.
    Mantus, D.
    Tyrrell, B.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A255 - A255
  • [19] Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs
    Kojiro Maeda
    Masayuki Kaneko
    Mamoru Narukawa
    Teruyo Arato
    [J]. Orphanet Journal of Rare Diseases, 12
  • [20] Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs
    Maeda, Kojiro
    Kaneko, Masayuki
    Narukawa, Mamoru
    Arato, Teruyo
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2017, 12
123